AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation ? the first in gastric ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the ... attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of a protease-cleavable maleimide tetrapeptide and topoisomerase which is an exatecan derivative, produced in Chinese hamster ovary cells by ...

Datopotamab deruxtecan is comprised of a humanised anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of a protease-cleavable maleimide tetrapeptide and topoisomerase which is an exatecan derivative, produced in Chinese hamster ovary cells by ...

Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor ...